Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02414854 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)
A Phase 3 study of Asthma, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,902
- Enrollment target
- 20
- Study locations
NCT02414854 is a Phase 3 study of Asthma that has completed, run by Sanofi. The registered enrollment target is 1,902 participants, above the 1,558-participant average among 374 other Asthma trials with a reported enrollment target (22% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT02414854, a Phase 3 study of Asthma, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,902 participants
- Enrollment target
- 20
- Study locations
Study Summary
Primary Objective: To evaluate the efficacy of dupilumab (SAR231893 / REGN668) in participants with persistent asthma. Secondary Objectives: * To evaluate the safety and tolerability of dupilumab. * To evaluate the effect of dupilumab on improving participant-reported outcomes including health-related quality of life. * To evaluate dupilumab systemic exposure and incidence of anti-drug antibodies.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dupilumab
- DRUG Inhaled corticosteroid (ICS) therapy
- DRUG Albuterol/Salbutamol
- DRUG Levalbuterol/Levosalbutamol
Study Locations (20)
California
- Investigational Site Number 840109 - Bakersfield
- Investigational Site Number 840052 - Costa Mesa
- Investigational Site Number 840116 - Fresno
- Investigational Site Number 840045 - Long Beach
- Investigational Site Number 840011 - Los Angeles
- Investigational Site Number 840061 - Los Angeles
- Investigational Site Number 840097 - Los Angeles
- Investigational Site Number 840019 - Mission Viejo
- Investigational Site Number 840125 - Newport Beach
- Investigational Site Number 840041 - North Hollywood
- Investigational Site Number 840036 - Redwood City
- Investigational Site Number 840020 - Rolling Hills Estates
- Investigational Site Number 840074 - Roseville
- Investigational Site Number 840021 - San Jose
Arizona
- Investigational Site Number 840056 - Flagstaff
- Investigational Site Number 840099 - Gilbert
- Investigational Site Number 840087 - Scottsdale
Alabama
- Investigational Site Number 840047 - Birmingham
Arkansas
- Investigational Site Number 840132 - Little Rock
Colorado
- Investigational Site Number 840004 - Centennial
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,902 participants |
| Start Date | 2015-04-27 |
| Est. Completion | 2017-11-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02414854
The ClinicalTrials.gov registry entry for NCT02414854 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,902 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,558-participant average among 374 other Asthma trials with a reported enrollment target (22% higher). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT02414854 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT02414854 about?
NCT02414854 is a clinical study titled "Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)". Primary Objective: To evaluate the efficacy of dupilumab (SAR231893 / REGN668) in participants with persistent asthma. Secondary Objectives: * To evaluate the safety and tolerability of dupilumab. * To evaluate the effect of dupilumab on improving participant-reported outcomes including health-re...
What is the current status of trial NCT02414854?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,902 participants. The study started on 2015-04-27. Estimated completion is 2017-11-23.
What conditions does trial NCT02414854 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT02414854?
The interventions under investigation include: Placebo (DRUG), Dupilumab (DRUG), Inhaled corticosteroid (ICS) therapy (DRUG), Albuterol/Salbutamol (DRUG), Levalbuterol/Levosalbutamol (DRUG).
Who is sponsoring clinical trial NCT02414854?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02414854 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.